When the COVID-19 pandemic began producing widespread reports of hair loss in 2020 and 2021, dermatologists recognised it immediately as telogen effluvium, the well-characterised shedding that follows major systemic illness. What wasn't clear was whether COVID-associated hair loss would behave like typical post-illness telogen effluvium (self-limiting, resolving within 6–9 months) or whether something about the SARS-CoV-2 infection or its inflammatory aftermath would drive a more persistent course.

A malnourished Afghan child, weighing 14 pounds (6.4 kg) at 18 months of age, is treated by a US Army medical team member in Paktya, Afghanistan.
Figure 1. A malnourished Afghan child, weighing 14 pounds (6.4 kg) at 18 months of age, is treated by a US Army medical team member in Paktya, Afghanistan. · Capt. John Severns — Wikimedia Commons (Public domain)

Three years of longitudinal data from the UK Biobank COVID follow-up cohort, 40,287 adults who contracted confirmed COVID-19 between March 2020 and June 2022, with regular health assessments every six months, now provides the most comprehensive picture we have. The data, published in The Lancet in late 2024, documented hair loss rates, patterns, and recovery trajectories in this large population.

At peak shedding (approximately 3–4 months post-infection), 42% of women and 21% of men reported clinically noticeable hair loss above baseline. This matches the expected sex difference in telogen effluvium, women have longer hair cycles and a larger resting follicle proportion, making them more susceptible to mass telogen shedding. The vast majority, 79% of those who reported shedding, had substantially recovered within 12 months. That's consistent with typical post-illness telogen effluvium.

The concerning findings are in the 21% who didn't follow the typical recovery trajectory. In this subgroup, persistent hair loss at 24 months was associated with: female sex (OR 1.8), ICU admission (OR 2.4), post-COVID syndrome diagnosis (OR 2.9), and elevated inflammatory markers at 3 months post-infection, specifically elevated CRP and IL-6 (OR 2.2 for each). The association with persistent inflammation is mechanistically coherent: elevated IL-6 is known to be a potent driver of telogen induction, and chronic systemic inflammation can maintain elevated IL-6 levels long after viral clearance, continuously pushing follicles toward telogen.

Importantly, the data also found a small but statistically significant association between COVID-19 infection and acceleration of pre-existing androgenetic alopecia. In men aged 25–55 who had documented androgenetic alopecia at baseline, those who contracted COVID-19 showed faster Norwood scale progression at 24 months versus matched controls, a mean difference of 0.3 Norwood categories. This is a modest but consistent finding across the full cohort, and it's biologically plausible: the acute inflammatory episode may have accelerated the inflammatory component of androgenetic alopecia that is increasingly recognised as a co-driver of follicle miniaturisation.

For the 2030 treatment landscape, the COVID data is a reminder that hair loss has multiple inputs, hormonal, immune, inflammatory, nutritional, and that systemic events can perturb these systems in ways that outlast the original insult. The most effective future treatments will almost certainly need to address multiple pathways simultaneously. The patients who recovered fastest from post-COVID hair loss tended to be those who already had robust anti-inflammatory nutrition and lifestyle baselines, suggesting that the overall inflammatory load a patient carries influences their follicle resilience in ways that go well beyond just treating the scalp.